Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.
Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, PA, USA.
Expert Rev Vaccines. 2021 Jun;20(6):717-728. doi: 10.1080/14760584.2021.1925113. Epub 2021 Jun 24.
Asthma is one of the most common chronic respiratory conditions worldwide and can be exacerbated by influenza. Findings from early trials demonstrated a higher risk of medically significant wheezing in otherwise healthy young children (aged 6 - 23 months) following administration of the Ann Arbor-backbone live attenuated influenza vaccine (LAIV-AA). In more recent years, several additional studies have investigated the safety of LAIV-AA in older children (2 - 17 years of age) and adults with asthma or prior wheezing, but these findings have not yet been systematically evaluated.
We conducted a systematic literature review to assess and synthesize the evidence from all available studies on the safety of LAIV-AA in people aged 2 - 49 years with a diagnosis of asthma or recurrent wheezing.
Fourteen studies over 20 years, involving a total of 1.2 million participants, provided evidence that LAIV-AA was well tolerated with no safety concerns in individuals aged 2 - 49 years with a diagnosis of asthma or recurrent wheezing. These data can help inform guidelines for use of LAIV-AA in children and adults with a history of asthma or recurrent wheezing.
哮喘是全球最常见的慢性呼吸道疾病之一，可因流感而加重。早期试验的结果表明，在接受安阿伯骨干减毒活流感疫苗（LAIV-AA）接种后，原本健康的年轻儿童（6 至 23 个月龄）出现医学上显著喘息的风险更高。近年来，有几项额外的研究调查了 LAIV-AA 在患有哮喘或既往喘息的年龄较大的儿童（2 至 17 岁）和成年人中的安全性，但这些发现尚未得到系统评估。
我们进行了系统的文献综述，以评估和综合所有可用研究中关于诊断为哮喘或反复喘息的 2 至 49 岁人群中使用 LAIV-AA 的安全性证据。
20 年来的 14 项研究共涉及 120 万人，这些研究表明，LAIV-AA 在诊断为哮喘或反复喘息的 2 至 49 岁人群中耐受性良好，无安全性问题。这些数据有助于为有哮喘或反复喘息病史的儿童和成人使用 LAIV-AA 提供指导。
